澳大利亚生物技术公司CSL（CSL.AU）今日盘中股价大跌13.19%，引发市场广泛关注。
据悉，CSL宣布推迟其原定于2026财年完成的疫苗部门Seqirus分拆计划。公司表示，由于美国流感疫苗市场波动加剧，目前的市场条件不利于实现股东价值最大化，因此决定推迟分拆时间。
CSL在声明中指出，自8月份宣布分拆计划以来，美国流感疫苗接种率的下降速度超过预期。这一趋势促使公司下调了2026财年Seqirus业务的整体收入预期。CSL强调，公司将在市场条件有利于股东价值最大化时再考虑进行分拆。此前，CSL曾计划在明年6月前将CSL Seqirus分拆成一个独立的上市实体，并裁员约3000人。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.